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Abstract
Purpose To examine the preliminary survival outcomes
and treatment-related toxicity for elderly patients with
cervical cancer treated with radiotherapy (RT).
Methods Forty patients C75 years old with cervical
cancer who were treated with RT were evaluated. Of these
40 patients, 25 were classiﬁed as FIGO stage I or II and 15
as stage III or IVA. Thirty-ﬁve patients were treated with
radical RT (RRT), and ﬁve were treated with surgery plus
adjuvant RT (S ? ART). External beam radiotherapy
combined with high-dose-rate intracavitary brachytherapy
was performed on 31 patients who were treated with RRT
and on 2 patients who were treated with S ? ART because
of positive vaginal surgical margins. The patients’ median
age was 78 years (range 75–89 years). Concurrent che-
motherapy (CCT) was performed on ﬁve patients (RRT: 3,
S ? ART: 2).
Results The median follow-up period was 20 months
(range 1–85 months). Only one patient could not complete
RT. The 3-year overall and disease-speciﬁc survival (OS
and DSS) rates for all patients were 58 and 80%, respec-
tively. Five patients experienced Grade 3 acute toxicity;
two were treated with RRT (2/35), and three were treated
with S ? ART (3/5, 2 of them with CCT). Two patients
experienced Grade 3 late toxicity; one was treated with
RRT (1/35, with CCT) and the other was treated with
S ? ART (1/5). No Grade 4 or higher toxicity was
experienced.
Conclusions RRT for elderly patients with cervical can-
cer is generally effective and safe, but severe toxicity may
occur with more aggressive treatment modalities.
Keywords Cervical cancer  Radiotherapy 
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Introduction
The population of elderly people has been rapidly
increasing in Japan. According to statements by the Min-
istry of Health, Labor and Welfare, the average life
expectancy for men and women in 2008 was 79 and
86 years old, respectively [1]. In particular, the life
expectancy of a Japanese woman is the longest in the
world. With an increasingly aged society, the number of
elderly patients with various malignancies continues to
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patients has also been increasing due to changes in lifestyle
and viral infections. In Japan, malignant neoplasms have
the highest mortality rate, surpassing cerebrovascular and
heart diseases in 1981.
For cervical cancer, the most commonly afﬂicted age
group is women in their late 30s to early 40s; the afﬂiction
of young women is usually emphasized [2–4]. However,
the incidence of cervical cancer increases again after age
70, and the mortality rate increases with age. Therefore, the
increase in the ratio of elderly patients with cervical cancer
must be evaluated, and an appropriate treatment modality
should be identiﬁed. Surgery and/or radiotherapy (RT) are
the radical treatment modalities for cervical cancer. For
advanced-stage disease, RT with or without concurrent
chemotherapy (CCT) is usually the radical treatment of
choice. For early-stage disease, the survival outcomes of
surgery and RT are known to be similar [5–8]. Although
RT seems to be a less invasive treatment, its long-term
complications and negative impact on sexual function
when compared with surgery are important considerations
for younger patients [9–11]. Therefore, there is a trend
emerging in which surgery is usually used for younger
patients and RT is used for elderly patients. However,
although it is obvious that RT plays an important role in the
treatment of most stages (I–IVA) of cervical cancer, the
recent increase in the elderly population may further
increase RT’s importance [12, 13].
In this study, we retrospectively analyzed the pre-
liminary survival outcomes and evaluated treatment-related
toxicity for Japanese elderly patients (C75 years old) with
cervical cancer treated with RT.
Materials and methods
Patients
At Kobe University Hospital between 2000 and 2009, 40
patients aged 75 or older who had cervical cancer and were
treated with RT as the radical or postoperative adjuvant
modality were retrospectively evaluated. Patients who
received only palliative RT were excluded. Those patients
who were followed for \6 months, except when this was
due to recurrence or death, were also excluded. Between
2000 and 2005, 9 patients were treated, whereas 31 were
treated between 2006 and 2009. Clinical staging was per-
formed according to the International Federation of
Gynecology and Obstetrics (FIGO) stages [14]. Among the
40 patients, 35 were treated with radical RT (RRT), and 5
were treated with surgery and adjuvant RT (S ? ART). Six
patients had pelvic nodal metastases (4 were clinical, 2
were pathological). Thirty-eight tumors were histologically
conﬁrmed as squamous cell carcinoma (SCC), and two
were conﬁrmed as adenocarcinoma. On the Karnofsky
Performance Scale (KPS), 20 patients had scores[70, 17
had scores between 50 and 70, and 3 had scores \50.
Twenty-ﬁve patients had stage I or II disease (IA: 1, IB: 4,
IIA: 7, IIB: 13), and 15 had stage III or IVA disease (IIIA:
2, IIIB: 11, IVA: 2). The median age was 78 years (range
75–89 years). In addition, 29 of the 40 patients had con-
current medical complications. Three patients had a pre-
vious history of malignancy (breast cancer, colon cancer,
and malignant lymphoma), and one had early-stage lung
cancer concurrent with the advanced cervical cancer.
Patient information according to clinical factors is shown
in Table 1.
Table 1 Patient information according to clinical factors
Factors Number of patients (total = 40) %
Treatment period
2000–2005 9 22.5
2006–2009 31 77.5
Age (years old)
B80 27 67.5
[81 13 32.5
Median age (range) 78 (75–89)
Karnofsky performance scale score
[70 20 50
50–70 17 42.5
\50 3 7.5
Stage (FIGO)
IA 1 2.5
IB 4 10
IIA 7 17.5
IIB 13 32.5
IIIA 2 5
IIIB 11 27.5
IVA 2 5
Histology
SCC 38 95
Adenocarcinoma 2 5
Nodal metastasis
Yes 6 15
No 34 85
Medical complications
Yes 29 72.5
No 11 27.5
History of other cancers
Yes 4 10
No 36 90
SCC squamous cell carcinoma
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In our institution, RRT is recommended as the deﬁnitive
treatment for patients with cervical cancer C75 years old.
Surgery is considered if the following criteria are met:
young age, high KPS score ([70), and FIGO I or II.
Medical complications and histology (adenocarcinoma) are
also important considerations. In addition, the patient’s
desired treatment choice (RT or surgery) is also considered.
Indications for the use of ART are based on pathological
ﬁndings (nodal metastasis, parametrium invasion, surgical
margin, vascular invasion, and/or lymphatic invasion).
Based on this institutional guideline, 35 patients were
treated with RRT, and the remaining 5 were treated with
S ? ART. Among the 35 patients treated with RRT, 31
were treated with external beam radiotherapy (EBRT)
combined with high-dose-rate intracavitary brachytherapy
(HDR-ICBT), 3 were treated with EBRT alone, and 1 was
treated with HDR-ICBT alone. The four patients treated
with EBRT or HDR-BT alone had KPS scores = 50 or
less. Of the 31 patients treated with EBRT combined with
HDR-ICBT, 2 received boost irradiation for pelvic lymph
node metastases. Two of the three patients treated with
EBRT alone received boost irradiation for the primary
tumor instead of HDR-BT. Among the ﬁve patients treated
with S ? ART, three received EBRT alone, and two
received EBRT combined with HDR-ICBT because of
positive vaginal surgical margins. CCT using a platinum-
based regimen was performed on ﬁve patients. Three were
treated with RRT with CCT, and two were treated with
S ? ART with CCT. At our institution, RRT with CCT is
performed on younger patients (\80) with high KPS scores
([70) and FIGO IIB or higher. The presence of medical
complications is also an important consideration. Based on
these criteria, three patients were treated with RRT with
CCT. Adjuvant CCT has been performed on patients with
multiple pathological risk factors (at least 3) since 2008.
Postoperative KPS score ([70) is also considered to be
important because S ? ART with CCT is a very aggressive
treatment for elderly patients; two were ultimately treated
with this modality. The patient distribution per treatment
modality is shown in Table 2.
The patients who received EBRT combined with HDR-
ICBT were initially treated with whole pelvic irradiation
using a box ﬁeld and high-energy 10 MV X-ray photons
from a linear accelerator with a daily fraction size of
1.8–2.0 Gy delivered ﬁve times per week. A centrally
shielded ﬁeld using anterior/posterior opposed portals was
applied just before starting HDR-ICBT. The patients who
received EBRT alone were also initially treated with whole
pelvic irradiation. A boost to the primary tumor was
delivered using a three-dimensional conformal technique,
and a pelvic lymph node boost was delivered using the
anterior/posterior opposed portals. The median total dose
of EBRT was 50.4 Gy (range 16.2–61.2 Gy). The HDR-
ICBT was done with a Microselectron HDR (Nucletron,
The Netherlands) using a 192-Iridium remote afterloading
system at 1-week intervals during the period of EBRT.
The median total dose to point A was 20.0 Gy (range
4.5–31.0 Gy) with a single fraction size of 4.0–6.5 Gy.
Treatment planning for HDR-ICBT was performed at each
irradiation using PLATO Brachytherapy Planning System
version 3.2 (Nucletron, The Netherlands). Evaluation of the
rectal and bladder dose was performed according to ICRU
Report 38 [15].
Follow-up, evaluation of treatment-related toxicity,
and statistical analysis
After completion of their treatment, most patients were
followed up by gynecological and radiation oncologists
every month during the ﬁrst year, primarily because elderly
patients tolerate RT less well and unexpected toxicity
might be experienced. However, patients who lived far
from our institution were followed up every 2–3 months.
Afterward, follow-up was conducted every 3–6 months
to detect recurrence and late toxicity. A gynecological
examination was performed, and the tumor marker was
checked at every visit. SCC Antigen was used for patients
who had SCC, and Carcinoembryonic Antigen (CEA) was
usually used for patients who had adenocarcinoma.
Radiographic examinations (CT scan or MRI) were per-
formed as necessary.
Both acute and late treatment-related toxicity were
evaluated using medical records and CTC-AE version 4.0
[16]. Acute toxicity was deﬁned as those events that
occurred within 90 days from the start of the treatment, and
late toxicity was deﬁned as those events that either occurred
[90 days from the start of the treatment or persisted
beyond 90 days.
Table 2 Patient distribution per treatment modality
Number
of patients
Use
of CCT
RRT
EBRT ? HDR-ICBT (with nodal boost) 31 (2) 3
EBRT (with local boost) 3 (2) 0
HDR-ICBT 1 0
S ? ART
EBRT 3 1
EBRT ? ICBT 2 1
RRTradicalradiotherapy,EBRTexternalbeamradiotherapy,HDR-ICBT
high-dose-rate intracavitary brachytherapy, S surgery, ART adjuvant
radiotherapy, CCT concurrent chemotherapy
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software (Systat Corporation, CA, USA). Survival rates
were calculated with the Kaplan–Meier method and com-
pared with the use of log-rank test. The follow-up period
was calculated from the start of the treatment. P values
\0.05 were considered statistically signiﬁcant.
Results
Patient status and patterns of failure
The median follow-up period for all patients was
20 months (range 1–85 months). The median follow-up
period for survivors was also 20 months (range
6–85 months). Of the initial 40 patients, 38 completed the
treatment as planned, 1 completed with a delay due to
concomitant heart disease, and 1 could not complete the
treatment because of acute toxicity. These two patients
who experienced delay or cancellation had lower KPS
scores (\50). Seven patients experienced recurrence: four
locally, one in the para-aortic lymph nodes, one distantly,
and one with only tumor marker (SCC Antigen) elevation.
Even though a thoracic-abdominal contrast enhanced CT
scan, a pelvic MRI, a gynecologic examination and cytol-
ogy were performed, a recurrent tumor could not be
detected at any site. However, this patient was presumed
to have microscopic recurrence because SCC Antigen
increased continuously. Regarding the clinical stages, one
patient was classiﬁed as IIA, one as IIIA, and ﬁve as IIIB.
Six of the seven patients with recurrence were treated with
RRT, and one was treated with S ? ART. During the
period of this study, nine patients died. Among them, ﬁve
died because of the primary disease, and four died from
other causes. The patient who could not complete the
treatment had persistent disease and died of the primary
disease. Of the remaining two patients who experienced
recurrence, one with the para-aortic lymph nodes
metastases is alive with the disease and one with tumor
marker elevation apparently died from a different cause.
The patient who had early-stage lung cancer concurrently
with the cervical cancer received the left lower lobe
resection after completion of RT. The pathological diag-
nosis was adenocarcinoma, pT2N0M0. This patient expe-
rienced multiple bone metastases (bilateral sacroiliac joints
and lumber spine) about 22 months after surgery. Bis-
phosphonate has been continuously administered, and the
patient is doing well without pain.
Preliminary survival outcomes
The 3-year overall and disease-speciﬁc survival (OS and
DSS) rates for all the patients were 58 and 80%, respec-
tively (Fig. 1a, b). The 3-year OS rate for patients in FIGO
stage I or II was 69%, and the rate for stage III or IVA
patients was 40% (P = 0.04). The 3-year DSS rate for
patients in FIGO stage I or II was 89% and that for stage III
or IVA patients was 66% (P = 0.04). The patients were
also divided into two groups according to age; there were
27 patients aged B80 years with a median follow-up of
26 months (range 1–85 months) and 13 patients aged
[80 years with a median follow up of 14 months (range
7–61 months). The 3-year OS rates for patients aged B80
and[80 years were 62 and 42%, respectively (P = 0.89).
The 3-year DSS rates for patients aged B80 and[80 years
were 75 and 100%, respectively (P = 0.21). Survival was
also analyzed according to KPS score. The 3-year OS rates
for patients with KPS scores [70 and B70 were 61 and
55%, respectively (P = 0.15). The 3-year DSS rates for
patients with KPS scores[70 and B70 were 92 and 65%,
respectively (P = 0.11).
Treatment-related toxicity
The details regarding acute toxicity are shown in Table 3.
The most common acute toxicity was diarrhea (18/40
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Fig. 1 Preliminary overall and
disease-speciﬁc survival (OS
and DSS) rates for all patients
(n = 40) using the Kaplan–
Meier method with a median
follow-up of 20 months (range
1–85 months). The 3-year OS
and DSS rates were 58% (a)
and 80% (b), respectively
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123patients, 45%). Grade 3 acute toxicity occurred in ﬁve
patients, but no Grade 4 or greater acute toxicity was
experienced. Among the ﬁve patients with Grade 3 acute
toxicity, two were treated with RRT (2/35 patients, 5%)
and three were treated with S ? ART (3/5 patients, 60%).
As for the patients treated with RRT, one experienced
Grade 3 diarrhea and selectively cancelled her treatment at
16.2 Gy after nine fractions, and the other experienced
Grade 3 cystitis. As for the patients treated with S ? ART,
one receiving CCT experienced a Grade 3 small intestine
infection during RT and a urinary tract obstruction soon
after the completion of RT, the different one receiving
CCT experienced Grade 3 cystitis during RT, and the
remaining one experienced a small intestine obstruction
soon after RT. The patient who could not complete RT was
managed by the administration of anti-diarrheal agents and
continuous intravenous transfusion. RT was postponed, but
after recovery from the diarrhea, the patient refused to
restart RT. The patients who experienced cystitis or small
intestine infections were managed by the administration of
antibiotics and intravenous transfusions without delaying
the RT. The urinary tract obstruction was resolved by
urological intervention. The small intestine obstruction was
managed by conservative treatment, such as fasting, anti-
biotic administration, and continuous intravenous transfu-
sion. In both the urinary tract and small intestine
obstructions, abdominal CT scans were performed imme-
diately after the symptoms occurred, and progressive dis-
ease was excluded.
Currently, Grade 3 late toxicity has occurred in two
patients (2/40 patients, 5%). One of these two patients
(treated with RRT with CCT) experienced Grade 3 hem-
orrhagic cystitis. The other patient (treated with S ? ART)
experienced a Grade 3 acute small intestine obstruction and
a Grade 3 late small intestine obstruction. No Grade 4 or
greater late toxicity was experienced. The hemorrhagic
cystitis was managed by endoscopic hemostasis. The small
intestine obstruction was also managed by conservative
treatment. Abdominal CT scans were performed in both
cases and progressive disease was excluded before starting
the toxicity management. The details regarding late toxic-
ity are shown in Table 4.
Discussion
Choosing a treatment for elderly patients with various
malignancies is usually difﬁcult. Careful evaluation of their
general condition and concomitant medical problems must
be performed before the treatment begins. Compared with
young patients, safer and more effective modalities should
be chosen because severe toxicity may lead to cancellation
or delay of the treatment and subsequent loss of quality of
life [17–21]. Generally, RT is thought to be less invasive
than surgery or chemotherapy. Moreover, with recent
technical developments, a reduction of radiation-related
toxicity has been achieved, and the safety of RT is
Table 3 Acute treatment-
related toxicity according to
treatment modality (CTC-AE
version 4.0)
RRT radical radiotherapy,
S surgery, ART adjuvant
radiotherapy, CCT concurrent
chemotherapy
a Same patient
RRT (use of CCT), total: 35 S ? ART (use of CCT), total: 5
Gastrointestinal
Grade 1–2 Diarrhea: 16 (2), gastrointestinal
pain: 2
Diarrhea: 1(1)
Grade 3 Diarrhea: 1 Intestinal infection: 1(1)
a,
intestinal obstruction: 1
Grade 4 0 0
Genitourinary
Grade 1–2 Urinary frequency: 3, cystitis: 1 Urinary tract obstruction: 1
Grade 3 Cystitis: 1 Cystitis: 1, urinary tract
obstruction: 1(1)
a
Grade 4 0 0
Table 4 Late treatment-related toxicity according to treatment
modality (CTC-AE version 4.0)
RRT (use of CCT),
total: 35
S ? ART (use of CCT),
total: 5
Gastrointestinal
Grade 1–2 Rectal bleeding: 2 0
Grade 3 0 Intestinal obstruction
Grade 4 0 0
Genitourinary
Grade 1–2 Cystitis: 2 0
Grade 3 Cystitis: 1(1) 0
Grade 4 0 0
Other
Grade 1–2 Lymphedema: 2 Lymphedema: 1
Grade 3 0 0
Grade 4 0 0
RRT radical radiotherapy, S surgery, ART adjuvant radiotherapy,
CCT concurrent chemotherapy
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123increasing markedly. Therefore, RT is usually chosen for
elderly patients as a single modality, although sometimes
RT is combined with surgery and/or chemotherapy. Cer-
tainly, RT has taken on a greater role in aging societies
such as Japan. For example, in this study, just 9 patients
were treated from 2000 to 2005, but 31 were treated from
2006 to 2009.
Although there are several large retrospective studies
that have analyzed treatment results and prognostic fac-
tors, whether age is a negative prognostic factor remains
controversial [12, 13, 22–27]. However, most reports have
demonstrated that RT is effective for elderly patients. For
example, Ikushima et al. analyzed 727 patients with cer-
vical cancer and reported that the 5- and 10-year disease-
speciﬁc survival rates of 132 patients aged C75 years
were 66 and 57%, respectively. Thus, age was not a
signiﬁcant prognostic factor in that study [13]. Chen et al.
analyzed a total of 295 patients. They reported that the
5-year cause-speciﬁc survival rates of 79 patients aged
C70 years with respect to FIGO stage were 100% for IB,
85% for IIA, 78% for IIB, and 42% for III. Thus, again
age was not a signiﬁcant prognostic factor in this case
[26]. On the other hand, Brun et al. analyzed a total of
308 patients and reported that the 5-year survival rate of
31 patients aged C75 years was 42% and that age was a
signiﬁcant prognostic factor. However, they also reported
that the survival of those over 75 years was not different
from that of the rest of the population [23]. Although the
median follow-up of our study was shorter and the
number of cases is currently smaller, our observed sur-
vival rates are reasonable compared with previous reports.
Our results also indicate that the clinical stage might have
prognostic value in determining survival outcomes, but
age did not have prognostic value in such an elderly
population. Interestingly, the DSS rate of patients aged
[80 years was 100%. Whether ‘‘slow oncological pro-
gression’’ was associated with this result is unclear
because of the small number of patients and the short
follow-up period. Therefore, this result cannot be used as
evidence for a more limited treatment choice at present.
However, RRT alone should be the ﬁrst choice for
patients [80 years old. The survival rates of the patients
with high KPS scores ([70) were better than those with
low KPS scores (B70), but the difference was not sig-
niﬁcant. KPS was not a signiﬁcant prognostic factor in
this preliminary result, but it may have a large impact on
long-term survival. To evaluate survival outcomes accu-
rately and verify prognostic factors such as clinical stage,
age, and KPS, more cases need to be analyzed, a longer
follow-up period is needed, and the results need to be
compared with those of a younger population. Finally, the
most appropriate treatment choice for elderly patients
should be established.
Both acute and late toxicity should be evaluated care-
fully to establish a safe modality that achieves better sur-
vival outcomes and preserves the quality of life of elderly
patients with cervical cancer. Lindegaard et al. reported
that treatment was completed as planned in 68% of cases,
delayed in 29% of cases, and stopped prematurely in 3% of
cases. They concluded that elderly patients with cervical
cancer in otherwise good health may tolerate radical
radiotherapy with acceptable toxicity and reasonable sur-
vival rates [28]. In our study, 38 of 40 (95%) patients
completed the treatment as planned; 1 (2.5%) completed
after a delay and 1 (2.5%) could not complete the treat-
ment. The two patients who experienced delay or cancel-
lation of the treatment had KPS scores\50 and had RRT
performed, but they could not receive HDR-BT. This result
also indicates that elderly patients in good health can tol-
erate RRT (EBRT combined with HDR-ICBT). However,
those with a poor performance status should be treated
carefully; in some instances, a less invasive RRT (EBRT
alone) must be chosen. For elderly patients in good health,
tolerance for more aggressive treatment modalities such as
RRT with CCT or S ? ART with or without CCT should
be discussed carefully. In our study, 8 patients with KPS
scores [70 were treated with these more aggressive
modalities (RRT with CCT: 3, S ? ART: 3, S ? ART
with CCT: 2). As described above, the indications for the
use of these aggressive modalities involved age, KPS,
FIGO stage, and pathological risk factors. Regarding the
patients treated with RRT with CCT, all of them were
\80 years old and had KPS scores[70. Two of them were
FIGO IIB and the remaining one was IIIB. Regarding the
patients treated with S ? ART with or without CCT, 4
were 75, and 1 was 76 years old. All of them had KPS
scores [70 and had stage II disease (IIA: 2, IIB: 3).
Adjuvant CCT has been performed on patients with post-
operative KPS scores [70 and multiple pathological risk
factors (at least 3) since 2008. As a result, two were treated
with S ? ART with CCT. One had wide parametrium
invasion and both vascular and lymphatic invasion. The
other had a large tumor ([4 cm), parametrium invasion,
vascular invasion, and a positive vaginal surgical margin.
Although nodal metastasis was the most important prog-
nostic factor, two patients who had pathological nodal
metastasis did not receive adjuvant CCT. This was because
one had postoperative KPS score = 50, whereas the other
was one of the oldest patient treated in 2000 and adjuvant
CCT was not performed for elderly patients at that time.
Therefore, they were treated with S ? ART without CCT.
All of the patients treated with these aggressive modalities
completed the treatment without delay, but three of them
(37.5%) experienced Grade 3 acute toxicity during and
soon after the completion of RT. These results indicate that
these aggressive modalities are not always safe in terms of
1012 Arch Gynecol Obstet (2011) 284:1007–1014
123acute toxicity. As for late toxicity, although the median
follow-up was shorter, Grade 3 late toxicity was experi-
enced by 2 of 40 (5%) patients, and no Grade 4 or higher
late toxicity was experienced in our study. Several authors
reported that the occurrence rates of Grade 3 or greater late
morbidities were less than approximately 10%, and our
results are compatible with those of previous reports [12,
13, 28, 29]. However, we should emphasize that Grade 3
late toxicity was only experienced in patients treated with
the more aggressive modalities (RRT with CCT: 1,
S ? ART: 1). Aggressive modalities may be tolerable for
patients with a good performance status, but they can easily
cause severe acute or late toxicity compared with RRT
alone. Considering these results, when aggressive treatment
modalities are performed in elderly patients, management
of both acute and late toxicity is very important to avoid
delay or cancellation and to maintain quality of life. The
ﬁnding that patients with KPS scores [70 can tolerate
aggressive modalities with appropriate management,
whereas those with KPS scores\50 may not tolerate even
RRT alone, is also very important. KPS should be con-
sidered as one of the determinants in selecting a treatment
modality for elderly patients.
In conclusion, the number of elderly patients with
cervical cancer is increasing, and RRT provides good
survival outcomes with acceptable toxicity. However,
indications for the use of more aggressive modalities
should be assessed carefully, even for patients who are in
quite good health. Therefore, to establish appropriate
treatment strategies, including combinations of RT with
less invasive surgery and/or chemotherapy, larger studies
and prospective studies should be performed. Finally,
better survival outcomes and preservation of the quality
of life may be achievable for the growing elderly
population.
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